Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P01106
UPID:
MYC_HUMAN
Alternative names:
Class E basic helix-loop-helix protein 39; Proto-oncogene c-Myc; Transcription factor p64
Alternative UPACC:
P01106; A0A024R9L7; A0A087WUS5; A8WFE7; H0YBT0; P01107; Q14026
Background:
The Myc proto-oncogene protein, also known as c-Myc, plays a pivotal role in cell cycle progression, apoptosis, and cellular transformation. It acts as a transcription factor, binding DNA to activate growth-related genes and is crucial for angiogenesis and stem cell self-renewal. Its alternative names include Class E basic helix-loop-helix protein 39 and Transcription factor p64.
Therapeutic significance:
Myc's involvement in Burkitt lymphoma, characterized by chromosomal aberrations, highlights its potential as a therapeutic target. Understanding Myc's role could lead to innovative treatments for this and possibly other malignancies.